GLUCOCORTICOID HYPERTENSION AND NONADRENAL PHENYLETHANOLAMINE N-METHYLTRANSFERASE

被引:26
|
作者
KENNEDY, B
ELAYAN, H
ZIEGLER, MG
机构
[1] UCSD Medical Center, San Diego, CA 92103-8341
关键词
HYPERTENSION; GLUCOCORTICOID; EPINEPHRINE; DEXAMETHASONE; PHENYLETHANOLAMINE N-METHYLTRANSFERASE;
D O I
10.1161/01.HYP.21.4.415
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Several drugs that block epinephrine synthesis by inhibiting phenylethanolamine N-methyltransferase (PNMT) lower blood pressure in hypertensive rats. We investigated the mechanism by which these drugs lower blood pressure in rats made hypertensive with the glucocorticoid dexamethasone. We performed adrenalectomy or sham operation on several rats and then gave them either dexamethasone chronically or vehicle. The dexamethasone-treated adrenalectomized rats also received either the centrally acting PNMT inhibitor SKF 64139 chronically or an equal dose of the primarily peripherally acting PNMT inhibitor SKF 29661. Both SKF 64139 and SKF 29661 reduced blood pressure by more than 25 mm Hg. SKF 64139 also reduced PNMT activity in hypothalamus, medulla oblongata, skeletal muscle, and cardiac atria and ventricles; SKF 29661 inhibited PNMT in muscle and heart tissue by 40-75%, did not inhibit PNMT in hypothalamus, and inhibited PNMT by only 29% in medulla oblongata. PNMT activity in peripheral tissues was also more highly correlated with blood pressure than was PNMT activity in the brain areas studied. Neither drug reduced tissue epinephrine levels, but SKF 64139 elevated dopamine or norepinephrine levels or both in several tissues. We conclude that the blood pressure-lowering action of PNMT-inhibiting drugs in glucocorticoid hypertensive rats may be due to inhibition or peripheral nonadrenal PNMT. We speculate that elevations in nonadrenal PNMT may mediate glucocorticoid hypertension.
引用
收藏
页码:415 / 419
页数:5
相关论文
共 50 条
  • [21] Glucocorticoid control of phenylethanolamine N-methyltransferase gene expression: Implications for stress and disorders of the stress axis
    Wong, DL
    Ebert, SN
    Morita, K
    STRESS - MOLECULAR GENETIC AND NEUROBIOLOGICAL ADVANCES, VOLS 1 AMD 2, 1996, : 677 - 693
  • [22] Transcriptional silencing of glucocorticoid-inducible phenylethanolamine N-methyltransferase expression by sequential signaling events
    Evinger, Marian J.
    Powers, James F.
    Tischler, Arthur S.
    EXPERIMENTAL CELL RESEARCH, 2007, 313 (04) : 772 - 781
  • [23] GLUCOCORTICOID EFFECTS ON PHENYLETHANOLAMINE N-METHYLTRANSFERASE (PNMT) IN EXPLANTS OF EMBRYONIC RAT MEDULLA-OBLONGATA
    BOHN, MC
    DREYFUS, CF
    FRIEDMAN, WJ
    MARKEY, KA
    DEVELOPMENTAL BRAIN RESEARCH, 1987, 37 (1-2): : 257 - 266
  • [24] REGULATION OF ADRENAL PHENYLETHANOLAMINE N-METHYLTRANSFERASE GENE EXPRESSION IN A FETAL PROGRAMMING MODEL OF HYPERTENSION
    Khurana, Sandhya
    Phong Nguyen
    Grandbois, Julie
    Peltsch, Heather
    Lo, Suet
    Venkataraman, Krishnan
    Tai, T. C.
    FASEB JOURNAL, 2013, 27
  • [25] Kinetic and pH studies on human phenylethanolamine N-methyltransferase
    Wu, Qian
    McLeish, Michael J.
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2013, 539 (01) : 1 - 8
  • [26] PHENYLETHANOLAMINE N-METHYLTRANSFERASE IN THE BRAINS OF STREPTOZOTOCIN DIABETIC RATS
    FISCHER, KJ
    STEWART, JK
    ENDOCRINOLOGY, 1986, 119 (06) : 2586 - 2589
  • [27] CONFORMATIONAL REQUIREMENTS OF SUBSTRATES FOR ACTIVITY WITH PHENYLETHANOLAMINE N-METHYLTRANSFERASE
    GRUNEWALD, GL
    YE, QH
    KIEFFER, L
    MONN, JA
    JOURNAL OF MEDICINAL CHEMISTRY, 1988, 31 (01) : 169 - 171
  • [28] Hypoxia-regulated phenylethanolamine N-methyltransferase expression
    Wong, Dona Lee
    Tai, T. C.
    Wong-Faull, David C.
    Claycomb, Robert
    FASEB JOURNAL, 2008, 22
  • [29] PRIMARY STRUCTURE OF BOVINE ADRENAL PHENYLETHANOLAMINE N-METHYLTRANSFERASE
    WONG, DL
    YOO, YS
    LAU, K
    SCHILLING, JW
    NEUROPSYCHOPHARMACOLOGY, 1990, 3 (03) : 175 - 180
  • [30] EVIDENCE THAT DOPAMINE IS NOT A SUBSTRATE FOR ADRENAL PHENYLETHANOLAMINE N-METHYLTRANSFERASE
    PENDLETON, RG
    GESSNER, G
    MOLECULAR PHARMACOLOGY, 1975, 11 (02) : 232 - 235